Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell
Executive Summary
Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February.
You may also be interested in...
Asia Deal Watch: CANbridge Licenses Orphan Disease Candidates From Mirum, LogicBio
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.
Daiichi Sankyo Enters Europe's Cholesterol Market
The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.